Dyslipidaemia
Conditions
Keywords
Steroid sensitive nephrotic syndrome, Dyslipidemia, Atorvastatin
Brief summary
To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.
Detailed description
Abstract Background: Dyslipidemia is a common complication in children with steroid-sensitive nephrotic syndrome (SSNS), which often persists during remission. It increases the risk of early atherosclerosis, cardiovascular disease, and progressive kidney damage. Lifestyle and dietary measures are often insufficient, and evidence on the use of statins such as atorvastatin in this population remains fairly unexplored. Objective: To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome. Methods: This quasi-experimental study was conducted at the department of Pediatric Nephrology & Nephrology department, National Institute of Kidney Diseases & Urology, Dhaka. A total of 100 children aged between 8-18 years with SSNS having dyslipidemia in two consecutive measurements, 1 month apart while in remission and who were free of infection were enrolled in the study. Participants were quasi-randomized into two groups: group A (dietary advice only n=50) (control group) and group B (dietary advice plus atorvastatin, n=50) (intervention group). Lipid profiles (total cholesterol, Triglyceride, Low density Lipoprotein and High Density Lipoprotein) were measured at baseline, 1, 3 and 6 months. During study in total 9 patients were lost to follow up and 2 patients were withdrawn from study. Outcome variable was percentage of patients achieving target levels of lipid profile within 3 months and 6 months in both groups. Safety was also assessed by monitoring of adverse events.
Interventions
DRUGAtorvastatin
Atorvastatin 10 mg nightly dose
Sponsors
National Institute of Kidney Disease and Urology (NIKDU)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
This quasi-experimental study
Eligibility
Sex/Gender
ALL
Age
8 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children aged 8-18 years with known cases of steroid sensitive nephrotic syndrome * LDL ≥ 130 mg/dl in two consecutive serum fasting lipid profile, at least 4 weeks apart * while on remission * free of acute infection.
Exclusion criteria
* Children with previously diagnosed hyperlipidemia other than Nephrotic Syndrome. * Children with steroid resistant nephrotic syndrome * Children already on lipid lowering drugs * Secondary nephrotic syndrome. * Those parents/patients who refused to participate. 4\. Secondary nephrotic syndrome (SLE, amyloidosis etc.) 5. Nephrotic syndrome (initial episode). 6. Children taking Anti TB drug or anticonvulsant drugs. 7. Children having any active liver disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage of patients achieving target levels of lipid profile | 6 months | percentage of patients achieving target levels of lipid profile within 3 months and 6 months in both groups |
Countries
Bangladesh
Contacts
PRINCIPAL_INVESTIGATORSaieef Zaman, MD
National institute of kidney Disease & Urology
Outcome results
None listed